Division of Online Health Training, Innovation Incubator, Leuphana University Lüneburg, Lüneburg, Germany.
BMC Psychiatry. 2013 Nov 15;13:306. doi: 10.1186/1471-244X-13-306.
A diagnosis of diabetes mellitus types 1 or 2 doubles the odds of a comorbid depressive disorder. The combined diseases have a wide range of adverse outcomes, such as a lower quality of life, poorer diabetes outcomes and increased healthcare utilisation. Diabetes patients with depression can be treated effectively with psychotherapy, but access to psychological care is limited. In this study we will examine the efficacy and cost-effectiveness of a newly developed web-based intervention (GET.ON Mood Enhancer Diabetes) for people with diabetes and comorbid depressive symptoms.
METHODS/DESIGN: A two-arm randomised controlled trial will be conducted. Adults with diabetes (type 1 or type 2) with increased depression scores (> 22 on the German version of the Center for Epidemiological Studies Depression Scale (CES-D)) will be included. Eligible participants will be recruited through advertisement in diabetes patient journals and via a large-scale German health insurance company. The participants will be randomly assigned to either a 6-week minimally guided web-based self-help program or an online psychoeducation program on depression. The study will include 260 participants, which will enable us to detect a statistically significant difference with a group effect size of d = 0.35 at a power of 80% and a significance level of p = 0.05. The primary outcome measure will be the level of depression as assessed by the CES-D. The secondary outcome measures will be: diabetes-specific emotional distress, glycaemic control, self-management behaviour and the participants' satisfaction with the intervention. Online self-assessments will be collected at baseline and after a 2 months period, with additional follow-up measurements 6 and 12 months after randomisation. The data will be analysed on an intention-to-treat basis and per protocol. In addition, we will conduct an economic evaluation from a societal perspective.
If this intervention is shown to be cost-effective, it has considerable potential for implementing psychological care for large numbers of people with diabetes and comorbid depression in routine practice and improve health outcomes.
German Clinical Trial Register (DRKS): DRKS00004748.
1 型或 2 型糖尿病的诊断使合并抑郁障碍的可能性增加一倍。这两种疾病有广泛的不良后果,如生活质量下降、糖尿病结局较差和医疗保健利用增加。患有抑郁症的糖尿病患者可以通过心理治疗有效治疗,但获得心理保健的机会有限。在这项研究中,我们将研究一种新开发的基于网络的干预措施(GET.ON Mood Enhancer Diabetes)对患有糖尿病和合并抑郁症状的人的疗效和成本效益。
方法/设计:将进行一项双臂随机对照试验。将纳入患有糖尿病(1 型或 2 型)且抑郁评分升高(德国版流行病学研究中心抑郁量表(CES-D)> 22)的成年人。合格的参与者将通过糖尿病患者期刊的广告和一家大型德国健康保险公司招募。参与者将被随机分配到为期 6 周的最低限度指导的基于网络的自助计划或关于抑郁的在线心理教育计划。该研究将包括 260 名参与者,这将使我们能够在 80%的效力和 p = 0.05 的显著性水平下检测到具有 0.35 组效应大小的统计学显著差异。主要结局测量将是使用 CES-D 评估的抑郁水平。次要结局测量将是:糖尿病特异性情绪困扰、血糖控制、自我管理行为和参与者对干预的满意度。在线自我评估将在基线和 2 个月后进行收集,并在随机分组后 6 个月和 12 个月进行额外的随访测量。将根据意向治疗原则和方案进行数据分析。此外,我们将从社会角度进行经济评估。
如果这种干预措施被证明具有成本效益,它在常规实践中为大量患有糖尿病和合并抑郁的人提供心理保健并改善健康结果方面具有相当大的潜力。
德国临床试验注册处(DRKS):DRKS00004748。